/ Print /

  • linkedin
  • Increase Font
  • Sharebar

    Six things to know: How health execs might benefit from Trump’s plans




    Among the Trump campaign’s stated goals are to allow the re-importation of cheaper prescription drugs from overseas. “Although the U.S. pharmaceutical industry benefits from federal funding for research and clinical trials, it has long been recognized that these same drugs cost more in the United States compared to other countries,” says Bill Denton, MBA, RN, chief operating officer, Novia Strategies, Inc., a national healthcare consulting firm. “Therefore, allowing the re-importation of the same drugs—at a lower cost to payers, providers, and consumers—could lower the medication management costs for many acute and chronic diseases.”


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Follow Us On Twitter

    Find us on Facebook

    Latest Tweets Follow